NCT00038441View on ClinicalTrials.gov

Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

September 30, 1995

Primary Completion Date

February 28, 2003

Study Completion Date

August 31, 2005

Conditions

GliomaBrain Neoplasms

Interventions

DRUG

DTI-015

DTI-015 injected through a catheter into center of brain tumor.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Direct Therapeutics

All Listed Sponsors

collaborator

Direct Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER